glp 1 for addiction treatment GLP-1 Receptor Agonists in Treatment: The Next Big Thing or Just Hype? What GLP-1 Addiction Treatment Adds

The SURMOUNT-1 trial showed average weight loss of 20.2 percent at 72 weeks on the highest dose, a figure that stunned the medical community when it was first published

Type 2 Diabetes Segment Accounts for the Largest Share of the GLP-1 Market In terms of the target indication, the market is segmented into Alzheimer's Disease, non-alcoholic steatohepatitis, obesity, sleep apnea, and type 2 diabetes

doi: 10.2337/dc12-2006

MRI: magnetic resonance imaging Mechanisms of muscle loss associated with GLP-1RAs treatment Preservation of skeletal muscle is critical for metabolic health, physical function and long-term outcomes, making the study of mechanisms underlying muscle loss during GLP-1RA therapy clinically relevant

Furthermore, we did not analyze the role of GLP-1 RAs as potential adjuvant therapy before or in addition to MBS